-
Mashup Score: 6Retrospective Claims Data and Patient Reported-Outcomes from COMMANDS Trial in Lower-Risk MDS - 3 day(s) ago
Amy DeZern, MD, MHS, discusses a retrospective study on healthcare claims for patients with MDS treated with luspatercept and reviews patient-reported outcomes from the COMMANDS trial.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
A retrospective cohort study acalabrutinib and zanubrutinib are being increasingly adopted for the treatment of CLL/SLL in the community setting.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
A retrospective cohort study acalabrutinib and zanubrutinib are being increasingly adopted for the treatment of CLL/SLL in the community setting.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
A retrospective cohort study acalabrutinib and zanubrutinib are being increasingly adopted for the treatment of CLL/SLL in the community setting.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7
Amer Zeidan, MBBS, MHS, presents data from the IMerge phase 3 study on the efficacy of imetelstat in achieving red blood cell transfusion independence across different risk subgroups in patients with lower-risk myelodysplastic syndromes relapsed/refractory to erythropoiesis-stimulating agents.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 65Emavusertib Progresses to Phase 2 Study in AML and MDS - 2 month(s) ago
The TakeAim Leukemia trial aims to add emavusertib to the treatment paradigm of acute myeloid leaukemialeukemia and high-risk myelodysplastic syndrome.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Emavusertib Progresses to Phase 2 Study in AML and MDS - 2 month(s) ago
The TakeAim Leukemia trial aims to add emavusertib to the treatment paradigm of acute myeloid leaukemialeukemia and high-risk myelodysplastic syndrome.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7Emavusertib Progresses to Phase 2 Study in AML and MDS - 2 month(s) ago
The TakeAim Leukemia trial aims to add emavusertib to the treatment paradigm of acute myeloid leaukemialeukemia and high-risk myelodysplastic syndrome.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Monitoring Patients with GVHD - 3 month(s) ago
Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz discuss challenges in detecting and diagnosing chronic GVHD. The panel advocates for vigilant communication, early detection, and ongoing patient education for comprehensive post-transplant care.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Monitoring Patients with GVHD - 3 month(s) ago
Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz discuss challenges in detecting and diagnosing chronic GVHD. The panel advocates for vigilant communication, early detection, and ongoing patient education for comprehensive post-transplant care.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
Hear from a panel of hematologist-oncologists as they provide an overview of the diagnosis and treatment of myelodysplastic syndromes and offers comprehensive insights on the evolving treatment landscape. @HopkinsMedicine #oncology #hematology https://t.co/x2Xemc2e2q